---
document_datetime: 2026-01-27 14:10:59
document_pages: 12
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: minjuvi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.788415
conversion_datetime: 2026-01-29 11:40:23.578898
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## MINJUVI

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope   | Opinio   | Commi    | Product   | Summary   |
|----------------------|---------|----------|----------|-----------|-----------|
|                      |         | n/       | ssion    | Inform    |           |
|                      |         | Notific  | Decisio  | ation     |           |
|                      |         | ation 1  | n        | affecte   |           |
|                      |         | issued   | Issued 2 | d 3       |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                        |                                                                                                                                                  |                                       |                                       |                                                                                                                                                                                                                                                                                                                                                                                                                              | on          | amend ed on   |      |
|----------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|---------------|------|
| Variation type IB / EMA/VR/0000310661  | Variation type IB / EMA/VR/0000310661                                                                                                            | Variation type IB / EMA/VR/0000310661 | Variation type IB / EMA/VR/0000310661 | This was an application for a group of variations. B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted B.II.f.1 Change in the shelf- life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted | 18/12/ 2025 | 15/12/2 025   | SmPC |
| Variation type IA / EMA/VR/00003174 12 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia | 12/12/ 2025                           | N/A                                   |                                                                                                                                                                                                                                                                                                                                                                                                                              |             |               |      |

<div style=\"page-break-after: always\"></div>

|                                     | the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted   |             |     |             | manufacturing process of                        |
|-------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----|-------------|-------------------------------------------------|
| Variation type IA / 82              | A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing - A.5.b The activities for which the manufacturer/importer is responsible do not include                                                                                   | 27/11/ 2025 | N/A |             | EMA/VR/00003097 sites) batch release - Accepted |
| Variation type II / EMA/VR/00002559 | C.I.6 Change(s) to therapeutic indication(s) -                                                                                                                                                                                                                                                                          | 13/11/ 2025 | 025 | SmPC and PL | 75 C.I.6.a Addition of a new 15/12/2            |

<div style=\"page-break-after: always\"></div>

| therapeutic indication or modification of an approved one - Accepted Extension of indication to include in combination with lenalidomide and rituximab treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after at least one line of systemic therapy for MINJUVI, based on interim results from study INCMOR 0208-301 (inMIND); this is a phase 3, randomized, double-blind, placebo- controlled, multicenter study to evaluate the   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                        | in accordance. Version 2.1 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce minor changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection.                                                                                                                                                      |             |             |          |
|----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|----------|
| Variation type II / EMA/VR/00002696 25 | This was an application for a group of variations. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re-test period/storage period supported by real time data - Accepted B.I.d.1 Change in the re- test period/storage period or storage conditions of the active substance where no Ph. Eur. Certificate of Suitability covering the retest period is part of the approved dossier - B.I.d.1.c | 30/10/ 2025 | 15/12/2 025 | Annex II |

<div style=\"page-break-after: always\"></div>

| stability protocol - Accepted  B.I.b.2 Change in test  procedure for active  substance or starting  material/reagent/intermedia  te used in the  manufacturing process of  the active substance -  B.I.b.2.a Minor changes to  an approved test procedure  - Accepted  B.I.b.2 Change in test  procedure for active  substance or starting  material/reagent/intermedia  te used in the  manufacturing process of  the active substance -  B.I.b.2.a Minor changes to  an approved test procedure  - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| an approved test procedure  - Accepted  B.I.b.2 Change in test  procedure for active  substance or starting  material/reagent/intermedia  te used in the  manufacturing process of  the active substance -  B.I.b.2.a Minor changes to  an approved test procedure  - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance -   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.2.a Minor changes to an approved test procedure - Accepted  B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted  B.II.b.4 Change in the batch size (including batch size ranges) of the finished product - B.II.b.4.c The change requires assessment of the comparability of a biological/immunological medicinal product or the change in batch size requires a new bioequivalence study - Accepted  B.I.a.1 Change in the manufacturer of a starting material/reagent/intermedia te used in the   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                        | manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.e The change relates to a biological active substance or a starting material/reagent/intermedia te used in the manufacture of a biological/immunological product - Accepted   |             |                             |
|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----------------------------|
| Variation type IB / 36 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - to update Annex                                                                                                                                                             | 24/10/ 2025 | EMA/VR/00003026 15/12/2 025 |

<div style=\"page-break-after: always\"></div>

|                                        | Information and the RMP to change the due date for the Specific Obligation MOR208C310 (frontMIND), from 'December 2025' to 'December 2026'.                                                                               |             |             |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/000025667 5   | - Renewal - Accepted                                                                                                                                                                                                      | 24/07/ 2025 | 17/09/2 025 | Annex II | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for MINJUVI, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. The SOB relating to the B-MIND study is fulfilled and therefore deleted from the SmPC. In addition, the SOB relating to the frontMIND study has been amended and is included in its updated form in the SmPC: 'In order to confirm the efficacy and to re-confirm the safety profile of tafasitamab in combination with lenalidomide the applicant should submit the results of a phase 3, multicentre, randomized, double- blind, placebo-controlled trial comparing tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly- diagnosed diffuse large B-cell lymphoma (DLBCL)'. |
| Variation type IB / EMA/VR/00002613 95 | This was an application for a group of variations. B.II.d.1 Change in the specification parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.I.b.1 Change in the | 03/04/ 2025 | N/A         |          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                      | and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted                                                                                                                                                                                                                                                          |             |     |                                         |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|-----|-----------------------------------------|
| Variation type IB 88 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermedia te used in the manufacturing process of the active substance - B.I.b.2.c Other changes to a test procedure (including replacement or addition) for a reagent, which does not have a significant effect on the overall quality of the active substance - Accepted B.I.b.2 Change in test procedure for active | 12/02/ 2025 | N/A | / EMA/VR/00002449 substance or starting |

<div style=\"page-break-after: always\"></div>

|                            | te used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted B.I.a.4 Change to in- process tests or limits applied during the manufacture of the active substance - B.I.a.4.z Minor change of an analytical procedure for an in-process   |             |
|----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|
| PSUR / EMA/PSUR/0000269001 | PSUR / EMA/PSUR/0000269001                                                                                                                                                                                                                                                                                                                                                                                                                                                 | Maintenance |